patent.fyi
Applications  /  US 2026/0355222
United States Patent Application Publication

US 2026/0355222 A1

Published
Nov 12, 2026
Filed
May 13, 2024
Earliest date on the face
May 31, 2023
Classification
A61K 31/675
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1External beam radiation

What ifWhat if an external photon beam treats the malignant tumor?
Claim language“a pharmaceutical composition comprising brincidofovir”

A planning computed tomography scan defines the target and nearby organs. A linear accelerator delivers radiation from multiple angles, concentrating the prescribed dose in the target while limiting exposure to surrounding tissue.

1.1Image guided thermal ablation

What ifWhat if a percutaneous microwave antenna destroys the malignant lesion by heating it?
Claim language“a pharmaceutical composition comprising brincidofovir”

Computed tomography or ultrasound guides placement of the antenna in the lesion. Microwave energy heats tissue around the antenna and produces coagulative necrosis across the planned treatment volume.

1.1Antibody blockade of PD-1

What ifWhat if the composition contains a PD-1 blocking antibody as its sole active ingredient?
Claim language“a pharmaceutical composition comprising brincidofovir”

Intravenous infusion delivers the antibody for a tumor type treated with PD-1 blockade. The antibody binds PD-1 on T cells and blocks inhibitory signaling from its ligands, supporting immune activity against tumor cells.

1.2Selection by measured drug response

What ifWhat if eligibility depends on growth inhibition in a tumor sample exposed to the compound, regardless of TLE1 expression?
Claim language“low TLE1 expression”

A laboratory divides viable biopsy material among drug-treated wells and vehicle-control wells. A viability assay quantifies the difference after a fixed exposure period, and a prespecified inhibition threshold determines study eligibility.

1.2Selection by organ function

What ifWhat if eligibility depends on organ function and a measurable lesion, regardless of TLE1 expression?
Claim language“low TLE1 expression”

Baseline imaging documents a measurable lesion, and serum bilirubin and estimated glomerular filtration rate are checked against prespecified enrollment criteria. Serial imaging measures lesion size during the study to assess response.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

TLE1 selection in veterinary oncology

A veterinary oncology study applies the TLE1 selection procedure to dogs with malignant solid tumors. A pathology laboratory measures canine TLE1 messenger RNA in tumor biopsies and compares normalized expression with a reference distribution from canine tumors of the same histologic type. The study assigns dogs below a prespecified expression cutoff to a brincidofovir treatment cohort and measures tumor dimensions at scheduled imaging visits.

Component substitution

Targeted mass spectrometry for TLE1

Targeted liquid chromatography tandem mass spectrometry replaces an antibody-based TLE1 readout. The laboratory extracts proteins from a tumor-rich tissue section, digests them with trypsin, and adds stable isotope-labeled versions of two peptides unique to TLE1. The instrument measures the signal ratio of each native peptide to its labeled counterpart, and the laboratory normalizes the resulting protein measurement to total protein input. A specimen below the prespecified cutoff for this assay meets the TLE1 criterion for the brincidofovir treatment protocol.

Parameter or scale variation

Three-region sampling for TLE1 classification

A pathology laboratory samples three spatially separated regions of a resection specimen and measures normalized TLE1 expression in each region. Each region contains at least 50 percent viable tumor cells by pathology review. The protocol classifies the tumor as TLE1-low when at least two of the three measurements fall below the assay cutoff. The classification determines eligibility for the brincidofovir arm of the treatment protocol.

Combination with existing systems

TLE1 results in oncology order entry

A laboratory information system sends the normalized TLE1 value, assay identifier, specimen identifier, and quality status to an electronic oncology order entry system. The order entry system links the result to the current tumor diagnosis and displays the value alongside the cutoff for the reported assay. A result below the cutoff with passing quality controls makes the brincidofovir order set available for clinician review and authorization.

Imaging linked to biopsy and treatment

An oncology imaging archive stores a baseline scan with a persistent identifier for the lesion sampled for TLE1 testing. The biopsy record links that lesion identifier to the laboratory result, and the treatment record stores the date of the first brincidofovir administration for subjects who meet the TLE1 criterion. At follow-up, the imaging workstation retrieves the baseline annotation and records the same lesion's dimensions against the elapsed time from treatment initiation.

Automated or data-driven variant

Digital scoring of tumor TLE1 staining

A slide scanner digitizes a TLE1 immunohistochemistry slide, and a pathologist marks viable tumor regions on the image. Image analysis software segments nuclei within the marked regions, measures nuclear stain intensity, and assigns each nucleus to one of four intensity classes using thresholds set with control tissue. The software calculates a weighted score from the percentage of nuclei in each class and flags scores below a configured cutoff for review under the brincidofovir treatment protocol.

Specific version of a part

Film coated oral tablet

A compressed tablet contains a measured amount of brincidofovir with a filler, binder, and disintegrant. A water-soluble film coats the tablet, and a dissolution test measures drug release from the finished dosage form.

Bottled oral suspension

Micronized brincidofovir particles are dispersed in an aqueous vehicle with a wetting agent and a viscosity modifier. The bottle is shaken to redisperse settled particles before the required volume is measured with an oral syringe.

Nuclear staining score

A laboratory stains a formalin-fixed, paraffin-embedded tumor section with a TLE1 antibody. The assay combines the percentage of stained tumor cell nuclei and their staining intensity into a score and classifies scores below a prespecified cutoff as low.

Normalized tumor transcript measurement

A laboratory extracts RNA from a tumor-enriched biopsy section and measures TLE1 transcript abundance by reverse transcription quantitative polymerase chain reaction. The result is normalized to reference transcripts, and samples below a prespecified normalized abundance cutoff are classified as low.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2017/0368082 A1
Published
Dec 28, 2017
Filed
Jun 28, 2017
Class
A61K 31/675
Document BUS 2020/0138835 A1
Published
May 7, 2020
Filed
Dec 20, 2019
Class
A61K 31/675
Claim 1
Document A
Document B
1.1administering to the subject an effective amount of a pharmaceutical composition comprising brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof
For example, IV administration of brincidofovir using formulations of the present disclosure provided blood plasma concentrations of brincidofovir in humans that had previously demonstrated anti-viral potency in cytomegalovirus prevention and adenovirus treatment. The amount of BCV used in the IV formulations (e.g., about 10 mg or about 25 mg) was about one tenth of the amount of BCV required to achieve similar blood-plasma concentrations using oral dosing.
A · US 2017/0368082 A1 · ¶ 89
In another aspect, the present disclosure provides a method of treating a subject with a viral infection, the method comprising: administering to the subject an intravenous pharmaceutical composition comprising brincidofovir; a bulking agent; a buffer; and dextrose
B · US 2020/0138835 A1 · ¶ 43
1.2wherein the subject has a malignant tumor with low TLE1 expression.

An empty cell means only that no passage was reproduced there.

Statements in these documents
The compositions can be lyophilized (e.g., as a powder) for long-term storage.
A · US 2017/0368082 A1 · ¶ 4
The lyophilized formulations can be reconstituted (e.g., in an aqueous sugar solution) as biocompatible formulations for intravenous (IV) administration (e.g., to a subject in need thereof).
A · US 2017/0368082 A1 · ¶ 4
The compositions can be lyophilized (e.g., as a powder) for long-term storage.
B · US 2020/0138835 A1 · ¶ 4
The lyophilized formulations can be reconstituted (e.g., in an aqueous sugar solution) as biocompatible formulations for intravenous (IV) administration (e.g., to a subject in need thereof).
B · US 2020/0138835 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355222 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355222/, SHA-256 b31dc5362c56eb1c48d60677d67b22498b1c6855e86c3993b2626340608922cd
First published
Permanent addresshttps://patent.fyi/US20260355222/
Content fingerprint (SHA-256)b31dc5362c56eb1c48d60677d67b22498b1c6855e86c3993b2626340608922cd
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi